OV-329 is under clinical development by Ovid Therapeutics and currently in Phase I for Seizures. According to GlobalData, Phase I drugs for Seizures have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OV-329’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - OV-329 in Seizures

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OV-329 overview

OV-329 is under development for the treatment of resistant orphan epilepsy  associated with tuberous sclerosis complex, focal seizures (partial seizure), infantile spasms and drug addiction. The drug candidate is administered through oral and intravenous route. It acts by targeting GABA aminotransferase.
 It was also under development for the treatment of status epilepticus, acute and chronic seizures.

Ovid Therapeutics overview

Ovid Therapeutics is a biopharmaceutical company that primarily focus on developing treatments for neurological disorders. The company’s main activities carries out the development of targeted small molecule therapies. Its products in development include OV329, a next-generation GABA aminotransferase inhibitor, and OV888, a highly selective ROCK2 inhibitor, in collaboration with graviton biosciences. Ovid Therapeutics’ therapies are designed to serve patients with epilepsies and seizures. The company operates in the US. Ovid Therapeutics is headquartered in New York city, New York, the US.

For a complete picture of OV-329’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.